BDBM179895 US10287250, Compound C.13::US10752592, Compound TABLE C.-1::US9133125, Table C, Compound 13::US9656961, Example 00163

SMILES CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1cccc(O)c1

InChI Key InChIKey=AOOXYUOJIHILLE-UHFFFAOYSA-N

Data  4 KI  4 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 179895   

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataKi:  4.40nM ΔG°:  -11.4kcal/mole IC50:  340nMpH: 7.5 T: 2°CAssay Description:The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataKi:  4.40nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataKi:  4.40nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataKi:  4.40nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataIC50:  340nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataIC50:  340nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataEC50:  20nMAssay Description:The EC50 and Imax for μ opioid receptors was determined using a [35S]GTPγS binding assay. This assay measures the functional properties of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataIC50:  340nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataEC50:  20nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataEC50:  20nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM179895(US10287250, Compound C.13 | US10752592, Compound T...)
Affinity DataEC50:  20nMpH: 7.4Assay Description:The EC50 and Imax for μ opioid receptors was determined using a [I35S]GTPγS binding assay. This assay measures the functional properties of a compo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent